Key Highlights

  • COMPASS Pathways (NASDAQ:CMPS) rose 12.37% to USD 9.45, a day after a 27.31% drop.
  • Cognition Therapeutics (NASDAQ:CGTX) gained 8.37% to USD 0.769 ahead of a November 5, 2026 call.
  • Rockwell Medical (NASDAQ:RMTI) climbed 11.04% to USD 7.67 following a Vantive deal.
  • Bioventus (NASDAQ:BVS) fell 19.47% to USD 10.59 after third quarter results.
  • Emergent BioSolutions (NYSE:EBS) dropped 18.63% to USD 5.24 after Revenue fell 52%.

COMPASS Pathways (NASDAQ:CMPS) (up USD 1.04, 12.37%): Recovery Ahead of Earnings

Pre-market trading on November 3, 2026 had COMPASS Pathways (NASDAQ:CMPS) up 12.37% at USD 9.45, compared with a November 2, 2026 close of USD 8.41. That close came after a 27.31% decline. Market reports said Usona Institute had submitted a Marketing application to the FDA for psilocybin in major depressive disorder. The company gave no reason, so the link rests on market commentary.

Third quarter results are due November 3, 2026, with a call at 8:00 a.m. ET. The company expects to complete its rolling FDA submission for COMP360 in the fourth quarter of 2026, and COMP360 has not been approved. It has no product revenue, and its cash balance had not been disclosed in the sources reviewed.

Cognition Therapeutics (NASDAQ:CGTX) (up USD 0.0594, 8.37%): Penny Stock Inches Higher Before November 5

In pre-market trading on November 3, 2026, Cognition Therapeutics (NASDAQ:CGTX) rose 8.37% to USD 0.769. The only company release identified was a November 2, 2026 notice of its third quarter call at 8:30 a.m. ET on November 5, 2026, and it contains no new data.

Lead candidate zervimesine is investigational, and the FDA aligned on a pivotal Phase 3 trial in dementia with Lewy bodies, with a start targeted for mid-2027. Cash was about USD 34.8 million at June 30, 2026, which is expected to last into the fourth quarter of 2027. A Phase 3 program will likely need more capital, which makes dilution a key risk for this penny stock.

Rockwell Medical (NASDAQ:RMTI) (up USD 0.7626, 11.04%): A Dialysis Agreement Boosts Shares

After announcing a definitive agreement with Vantive, Rockwell Medical (NASDAQ:RMTI) rose 11.04% to USD 7.67 in pre-market trading on November 3, 2026. Rockwell will acquire Vantive's hemodialysis concentrates, monitors and water treatment systems, but the dialyzer portfolio is excluded. Closing is expected in mid-2027, subject to regulatory approvals.

The release content reviewed did not disclose the price or financing terms. Cash, equivalents and investments were USD 24.8 million at June 30, 2026, so funding remains an open question, and any Equity issuance could dilute shareholders. Integrating an Italian plant adds execution risk.

Bioventus (NASDAQ:BVS) (down USD 2.56, 19.47%): Lower Shares Despite Better Profit and Debt Reduction

Following its third quarter report on November 2, 2026, Bioventus (NASDAQ:BVS) fell 19.47% to USD 10.59 in pre-market trading on November 3, 2026. Net sales reached USD 142.4 million, up 2.7%, and adjusted EBITDA climbed to USD 28.4 million. Net sales guidance was revised to USD 590 million to USD 595 million.

Growth was modest, with U.S. sales up just 1.0%. The company continues to review strategic alternatives, and no transaction has been announced. Total debt, calculated from the balance sheet, was about USD 229.8 million, following a USD 15.0 million discretionary term Loan prepayment in the quarter.

Emergent BioSolutions (NYSE:EBS) (down USD 1.20, 18.63%): Revenue Decline and Reduced Outlook

Emergent BioSolutions (NYSE:EBS) dropped 18.63% to USD 5.24 in pre-market trading on November 3, 2026, after releasing third quarter results on November 2, 2026. Revenue came in at USD 110.0 million, down from USD 231.1 million, and the net loss was USD 32.7 million. Naloxone sales fell 42% to USD 43.5 million.

The company cut its 2026 revenue guidance to USD 600 million to USD 645 million from USD 645 million to USD 675 million, and its chief financial officer will retire effective December 31, 2026. The release did not disclose cash or total debt balances. Timing of government orders can make results uneven.

Summary of the Movers

The five names are reacting in different ways: a rebound at COMPASS Pathways, a pipeline-driven penny stock at Cognition Therapeutics, deal-driven gains at Rockwell Medical, and sharp declines at Bioventus and Emergent BioSolutions after quarterly reports. Readers should track the COMPASS results on November 3, 2026, the Cognition call on November 5, 2026, Rockwell's purchase price and financing, and the Bioventus strategic review. Pre-market Liquidity is thin, so the opening trade may differ from early quotes.